EVGN vs. ACST, ICU, FBRX, SLGL, MOVE, QLI, DRRX, TVGN, ITRM, and WINT
Should you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Acasti Pharma (ACST), SeaStar Medical (ICU), Forte Biosciences (FBRX), Sol-Gel Technologies (SLGL), Movano (MOVE), Qilian International Holding Group (QLI), DURECT (DRRX), Tevogen Bio (TVGN), Iterum Therapeutics (ITRM), and Windtree Therapeutics (WINT). These companies are all part of the "medical" sector.
Evogene (NASDAQ:EVGN) and Acasti Pharma (NASDAQ:ACST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability.
Evogene has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Acasti Pharma has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
Acasti Pharma has a net margin of 0.00% compared to Evogene's net margin of -423.39%. Acasti Pharma's return on equity of -13.18% beat Evogene's return on equity.
In the previous week, Evogene had 1 more articles in the media than Acasti Pharma. MarketBeat recorded 2 mentions for Evogene and 1 mentions for Acasti Pharma. Evogene's average media sentiment score of 0.33 beat Acasti Pharma's score of -0.01 indicating that Evogene is being referred to more favorably in the media.
Acasti Pharma received 92 more outperform votes than Evogene when rated by MarketBeat users. Likewise, 70.52% of users gave Acasti Pharma an outperform vote while only 59.84% of users gave Evogene an outperform vote.
Evogene has higher revenue and earnings than Acasti Pharma. Evogene is trading at a lower price-to-earnings ratio than Acasti Pharma, indicating that it is currently the more affordable of the two stocks.
Evogene currently has a consensus target price of $3.62, suggesting a potential upside of 412.64%. Acasti Pharma has a consensus target price of $6.00, suggesting a potential upside of 98.02%. Given Evogene's higher possible upside, research analysts plainly believe Evogene is more favorable than Acasti Pharma.
10.4% of Evogene shares are owned by institutional investors. Comparatively, 6.1% of Acasti Pharma shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 13.5% of Acasti Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Evogene and Acasti Pharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Evogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
